EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype–genotype assessment

Kelly E Dunn iD, Andrew S Huhn, Patrick H Finan, Ami Mange, Cecilia L Bergeria, Brion S Maher, Jill A Rabinowitz, Eric C Strain, Denis Antoine

Addiction Biology · 2024-01 · 29 (1)

DOI: 10.1111/adb.13355 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Addiction Biology, online erschienen am 19.12.2023. Verfasst von Kelly E Dunn und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Analgesics, Opioid, Hydromorphone, Receptors, Opioid, mu. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, NIH HHS, National Institute on Drug Abuse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allelic variations in the A118G SNP of the OPRM1 gene change opioid signaling; however, evaluations of how allelic differences may influence opioid effects are lacking. This human laboratory paradigm examined whether the AA versus AG/GG genotypes determined opioid response profiles. Individuals with limited opioid exposure (N = 100) completed a five‐day within‐subject, double‐blind, placebo‐controlled, residential study. Participants were admitted (Day 1), received 4 mg hydromorphone (Day 2) and 0 mg, 2 mg and 8 mg hydromorphone in randomized order (Days 3–5) and completed self‐reported visual analog scale (VAS) ratings and Likert scales, observed VAS, and physiological responses at baseline and for 6.5 h post‐dose. Outcomes were analysed as peak/nadir effects over time as a function of genotype (available for N = 96 individuals; AG/GG = 13.5%, AA = 86.4%). Participants with AG/GG rated low and moderate doses of hydromorphone as significantly more positive (e.g., Good Effects VAS, coasting, drive, friendly, talkative, stimulation) with fewer negative effects (e.g., itchy skin, nausea, sleepiness), and were also observed as being more talkative and energetic relative to persons with AA. Persons with AG/GG were less physiologically reactive as determined by diastolic blood pressure and heart rate, but had more changes in core temperature compared with those with AA. Persons with AA also demonstrated more prototypic agonist effects across doses; persons with AG/GG showed limited response to 2 mg and 4 mg. Data suggest persons with AG/GG genotype experienced more pleasant and fewer unpleasant responses to hydromorphone relative to persons with AA. Future studies should replicate these laboratory findings in clinical populations to support a precision medicine approach to opioid prescribing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidHydromorphoneReceptors, Opioid, muHumansGenotypePhenotypePolymorphism, Single Nucleotide

Stichwörter der Autor:innen

A118GOPRM1addictionhydromorphoneopioidphenotyperisk

Substanzen

Analgesics, OpioidHydromorphoneOPRM1 protein, humanReceptors, Opioid, mu

Autor:innen und Institutionen

  • Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Anesthesiology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Yale School of Medicine, New Haven, Connecticut, USA.
  • Department of Mental Health, Johns Hopkins University School of Public Health, Baltimore, Maryland, USA.

ORCID-Profile: Kelly E Dunn

Förderung

  • NIDA NIH HHS
  • NIH HHS
  • National Institute on Drug Abuse
  • National Institutes of Health

Zitieren

APA

Dunn, K. E., Huhn, A. S., Finan, P. H., Mange, A., Bergeria, C. L., Maher, B. S., Rabinowitz, J. A., Strain, E. C., & Antoine, D. (2024). Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype–genotype assessment. Addiction Biology, 29(1). https://doi.org/10.1111/adb.13355

Vancouver

Dunn KE, Huhn AS, Finan PH, Mange A, Bergeria CL, Maher BS, et al. Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype–genotype assessment. Addiction Biology. 2024;29(1). doi:10.1111/adb.13355

BibTeX
@article{Dunn2024,
  author = {Dunn, Kelly E and Huhn, Andrew S and Finan, Patrick H and Mange, Ami and Bergeria, Cecilia L and Maher, Brion S and Rabinowitz, Jill A and Strain, Eric C and Antoine, Denis},
  title = {Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype–genotype assessment},
  journal = {Addiction Biology},
  year = {2024},
  volume = {29},
  number = {1},
  doi = {10.1111/adb.13355}
}
Kostenlos starten →